Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 

 Table of Contents  
Year : 2019  |  Volume : 15  |  Issue : 4  |  Page : 741-742

Apatinib for hepatocellular carcinoma

Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, China

Date of Web Publication14-Aug-2019

Correspondence Address:
Xin Ye
Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, 324 Jingwuweiqi Road, Jinan, Shandong Province 250021
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jcrt.JCRT_400_19

Rights and Permissions

How to cite this article:
Ni Y, Ye X. Apatinib for hepatocellular carcinoma. J Can Res Ther 2019;15:741-2

How to cite this URL:
Ni Y, Ye X. Apatinib for hepatocellular carcinoma. J Can Res Ther [serial online] 2019 [cited 2020 May 31];15:741-2. Available from: http://www.cancerjournal.net/text.asp?2019/15/4/741/264289

Primary hepatocellular carcinoma (HCC) ranks the second leading cause of cancer-related deaths in men worldwide with a poor prognosis.[1] For advanced patients, sorafenib is currently the standard therapy, which extended the overall survival (OS) by 2.8 months compared to best supportive care.[2] However, high cost, drug resistance, and severe side effects often lead to treatment discontinuation.[3] Apatinib (Hengrui Pharmaceutical Co., Ltd, Shanghai, China) is a novel, small-molecule, tyrosine kinase inhibitor which has higher selective inhibition of vascular endothelial growth factor receptor-2 than sorafenib, leading to suppression of tumor growth by targeting tumor angiogenesis. Apatinib was approved in China in 2014 as a subsequent-line treatment for patients with advanced gastric cancer. In addition, accumulating studies showed its potential antitumor activity across a broad range of advanced solid tumors including HCC.[4],[5] In a preliminary prospective study including 31 intermediate and advanced HCC patients receiving apatinib 500 mg daily, the response rate and disease control rate (DCR) were reported as 32.26% and 80.65%, respectively. The median time to tumor progression (TTP) was 4.8 months. Furthermore, 6- and 12-month OS rates were 73.8% and 55.4%, respectively.[6] In another recently reported retrospective study, 25 patients with unresectable or relapsed HCC were treated with apatinib until progressive disease or unacceptable toxicity. The median progression-free survival (PFS) and OS were 5 months and 13 months, respectively. The most common adverse effects were hand-foot syndrome, secondary hypertension, proteinuria, and liver dysfunction.[7]

Recently, there have been reports indicating that apatinib combined with other therapies can be used in HCC. In a single-center, randomized controlled trial, a total of 44 patients with moderate or advanced HCC were randomly assigned with transcatheter arterial chemoembolization (TACE) alone or combined treatment of TACE with apatinib. The objective response rate (ORR) at 12 months (35% vs. 9.09%) and median PFS (12.5 vs. 6.0 months) after treatment were significantly better in the combination therapy group. Although incidences of complications related to oral apatinib such as hypertension, hand-foot syndrome, and proteinuria were higher in the combination therapy group, no severe complications were observed.[8] Chen et al. reported similar results in a recently published retrospective study. Higher overall response rate was observed in TACE-apatinib combined group. The median TTP and OS in the TACE-apatinib group were longer than those in TACE-alone group (TTP: 6.3 vs. 3.5 months and OS: 13.0 vs. 9.9 months, respectively).[9] Yang et al. also showed that TACE together with apatinib significantly prolonged PFS and OS in advanced HCC compared with the TACE-alone group.[10] More recently, Xu et al. reported preliminary results of apatinib combined with SHR-1210 (anti-PD-1 antibody) for the treatment of HCC. Eight of 16 evaluable HCC patients achieved PR, including one in the apatinib 125-mg cohort and seven receiving apatinib 250 mg. The ORR and DCR were 50.0% and 93.8%, respectively. During the median follow-up duration of 7.8 months, the median PFS reached to 5.8 months. The 6-month PFS rate in patients receiving apatinib 250 mg was 51.3%, and the 9-month PFS rate was 41.0%.[11]

The main limitation of apatinib in HCC is that most studies were single-center, small-sample retrospective studies. Hence, international, large-scale, prospective, randomized clinical trials in multicenters are expected to be conducted to demonstrate the efficacy and safety of apatinib for the treatment of HCCs. We expect promising effects of apatinib in advanced HCC in the near future.

 > References Top

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7-30.  Back to cited text no. 1
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.  Back to cited text no. 2
Qiu WQ, Shi JF, Guo LW, Mao AY, Huang HY, Hu GY, et al. Medical expenditure for liver cancer in urban China: A 10-year multicenter retrospective survey (2002-2011). J Cancer Res Ther 2018;14:163-70.  Back to cited text no. 3
Ni Y, Ye X. Angiogenesis and apatinib: Can be used for the patients with non-gastic cancer? J Cancer Res Ther 2018;14:727-9.  Back to cited text no. 4
Meng M, Ye X, Yang X, Huang G, Wei Z, Ni Y, et al. Apatinib and S-1 combination therapy for the treatment of advanced head and neck neoplasms: Three case reports. J Cancer Res Ther 2019;15:442-6.  Back to cited text no. 5
Yu WC, Zhang KZ, Chen SG, Liu WF. Efficacy and safety of apatinib in patients with intermediate/advanced hepatocellular carcinoma: A prospective observation study. Medicine (Baltimore) 2018;97:e9704.  Back to cited text no. 6
Zhen L, Jiali C, Yong F, Han X, Hongming P, Weidong H. The efficacy and safety of apatinib treatment for patients with unresectable or relapsed liver cancer: A retrospective study. J Cancer 2018;9:2773-7.  Back to cited text no. 7
Lu W, Jin XL, Yang C, Du P, Jiang FQ, Ma JP, et al. Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: A single-center randomized controlled trial. Cancer Biol Ther 2017;18:433-8.  Back to cited text no. 8
Chen S, Yu W, Zhang K, Liu W. Comparison of the efficacy and safety of transarterial chemoembolization with and without apatinib for the treatment of BCLC stage C hepatocellular carcinoma. BMC Cancer 2018;18:1131.  Back to cited text no. 9
Yang Z, Chen G, Cui Y, Xiao G, Su T, Yu J, et al. The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: A retrospective study. Cancer Biol Ther 2019;20:321-7.  Back to cited text no. 10
Xu J, Zhang Y, Jia R, Yue C, Chang L, Liu R, et al. Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: An open-label, dose escalation and expansion study. Clin Cancer Res 2019;25:515-23.  Back to cited text no. 11


Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

  In this article

 Article Access Statistics
    PDF Downloaded57    
    Comments [Add]    

Recommend this journal